BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1451 related articles for article (PubMed ID: 15158130)

  • 1. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors in chick cerebral cortex.
    Zawilska JB; Niewiadomski P; Nowak JZ
    J Mol Neurosci; 2003 Apr; 20(2):153-62. PubMed ID: 12794309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
    Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
    J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes.
    Pineau N; Lelievre V; Goursaud S; Hilairet S; Waschek JA; Janet T; Muller JM
    Neuropeptides; 2001 Apr; 35(2):117-26. PubMed ID: 11384207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
    Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
    Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of neuropeptides of the secretin/VIP/PACAP family on cyclic AMP formation in the chick hypothalamus and cerebral cortex.
    Nowak JZ; Kuba K; Zawilska JB
    Pol J Pharmacol; 2000; 52(6):467-71. PubMed ID: 11334241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary adenylate cyclase-activating polypeptide type I receptors mediate cyclic AMP-dependent enhancement of neuronal acetylcholine sensitivity.
    Margiotta JF; Pardi D
    Mol Pharmacol; 1995 Jul; 48(1):63-71. PubMed ID: 7623776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on cyclic AMP formation in the hypothalamus and cerebral cortex of four avians and rat.
    Nowak JZ; Kuba K; Zawilska JB
    Pol J Pharmacol; 1999; 51(1):87-91. PubMed ID: 10389149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAC1 receptors in chick cerebral cortex: characterization by binding of pituitary adenylate cyclase-activating polypeptide, [125I]-PACAP27.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Neurosci Lett; 2003 Feb; 338(2):155-8. PubMed ID: 12566176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic AMP formation in chicken brain: effect of vasoactive intestinal peptide, peptide histidine-isoleucine (PHI), and some PHI-related peptides.
    Dejda A; Matczak I; Wiktorowska-Owczarek A; Nowak JZ
    Pol J Pharmacol; 2003; 55(5):747-51. PubMed ID: 14704471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
    Nilsson SF; De Neef P; Robberecht P; Christophe J
    Exp Eye Res; 1994 Apr; 58(4):459-67. PubMed ID: 7925682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide.
    Gottschall PE; Tatsuno I; Miyata A; Arimura A
    Endocrinology; 1990 Jul; 127(1):272-7. PubMed ID: 2361473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mitogen-stimulated proliferation of murine splenocytes by a novel neuropeptide, pituitary adenylate cyclase activating polypeptide: a comparative study with vasoactive intestinal peptide.
    Tatsuno I; Gottschall PE; Arimura A
    Endocrinology; 1991 Feb; 128(2):728-34. PubMed ID: 1989859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation induces pituitary adenylate cyclase-activating polypeptide receptor expression in PC-12 cells.
    Cavallaro S; D'Agata V; Guardabasso V; Travali S; Stivala F; Canonico PL
    Mol Pharmacol; 1995 Jul; 48(1):56-62. PubMed ID: 7623775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid desensitization of receptors for pituitary adenylate cyclase-activating polypeptide (PACAP) in chick cerebral cortex.
    Niewiadomski P; Nowak JZ; Sedkowska P; Zawilska JB
    Pol J Pharmacol; 2002; 54(6):717-21. PubMed ID: 12866731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM; Goursaud S; Medja F; Lelièvre V; Mounien L; Husson I; Brabet P; Jégou S; Janet T; Gressens P
    J Pharmacol Exp Ther; 2005 Aug; 314(2):745-52. PubMed ID: 15872042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
    Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
    J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.